BCR-ABL-IN-5

• UNSPSC Description:

  BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-AblWT and Bcr-AblT3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells[1].

• Target Antigen:

  Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bcr-abl-in-5.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NC1=NNC2=C1C(C3=CC=C(C=C3)C(N4CCN(CC4)C(C5=C(C=C(C=C5)Cl)Cl)=O)=O)=CC=C2

• Molecular Weight:

  494.37

• References & Citations:

  [1]Ashraf K El-Damasy, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. Eur J Med Chem. 2020 Dec 1;207:112710.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1795736-60-5